Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. The absence of fucose on the Fc N-glycan increases IgG1 Fc binding affinity to the FcγRIIIa on immune effector cells like natural killer cells. It results in increased antibody-dependent cellular cytotoxicity (ADCC). […]
Afucosylated mAb expression benefits therapeutic antibody efficacy
View
